Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01AG029656-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Aging (NIA) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Elderly patients who undergo anesthesia and non-cardiac surgery are subject to deterioration of brain function including the development of postoperative delirium (PD) and postoperative cognitive dysfunction (POCD). These disorders cause disability, distress for both patients and their families, are associated with other medical complications and account for significant additional health care costs. We currently use relatively primitive approaches to preventing and treating PD and POCD.
Dexmedetomidine is a drug used for sedation in critically ill patients that provides some pain relief and controls the bodies response to stress. The sedation produced by dexmedetomidine appears more similar to natural sleep than any other drug used for anesthesia and postoperative sedation. Data suggesting that dexmedetomidine can prevent delirium following cardiac surgery and the developing understanding of the causes of PD and POCD suggest that dexmedetomidine will be particularly effective.
Postoperative Delirium or PD and Postoperative Cognitive Dysfunction or POCD are syndromes of central nervous system dysfunction that significantly complicate the recovery of a proportion of elderly patients following surgery.
Delirium is typically a transient syndrome characterized by a de-novo appearance of several pathognomonic behaviors, including disorientation, decreased attention span, sensory misperceptions, a waxing-and-waning type of confusion, and disorganized thinking. PD typically occurs on postoperative days 1 to 3 and is associated with prolonged hospital stays, increased risks for morbidity and mortality and significant health care expenditures.
The neuroendocrine stress response to surgery, including the immediate postoperative period, remains an important potential etiologic factor. In particular, our data suggests that stress in the immediate postoperative period is poorly controlled by all anesthetic techniques and the normal diurnal variation in cortisol is suppressed in subjects who develop POCD.
Dexmedetomidine is a highly selective alpha 2A agonist currently approved for sedation in the ICU. Dexmedetomidine produces analgesia, sympatholysis, and a light sedation characterized by easy arousal. Its action converges on the endogenous substrates for natural sleep to produce their sedative action, an effect that could prove beneficial to elderly postoperative patients.
We hypothesize that treatment with dexmedetomidine will diminish both PD and POCD. The essential proposition is that modulation of perioperative stress can ameliorate perioperative delirium and cognitive dysfunction.
Based on both the concept of cognitive reserve as well as clinical experience, there is concern that patients with preoperative cognitive impairment are particularly vulnerable to POCD. In general, such patients have been excluded from previous studies. This study is unique in that we will assess all participants for mild cognitive impairment prior to surgery. Assessment of the impact of preexisting cognitive impairment is a secondary aim. A broad goal of this interdisciplinary project is to evaluate POCD, which is primarily an anesthesia concept, in the more general context of dementing illness as explored by geriatric psychiatry.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Precedex | Experimental | Precedex (Dexmedetomidine) |
|
| Placebo | Placebo Comparator | Placebo - normal saline |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Precedex (Dexmedetomidine) | Drug | 0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively. |
| Measure | Description | Time Frame |
|---|---|---|
| Delirium Battery | Number of Participants with occurrence of Post-Operative Delirium in Post-Anesthesia Care Unit (PACU) | Day 1 |
| Measure | Description | Time Frame |
|---|---|---|
| Neuropsychological Testing | Rate of change of cognitive function - data not collected because secondary analysis which was not performed | at 3 months postoperatively |
| Intraoperative Bradycardia |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jeff Silverstein, MD | Icahn School of Medicine at Mount Sinai | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Miami Medical Center | Miami | Florida | 33136 | United States | ||
| Johns Hopkins Bayview Medical Center |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28593326 | Result | Deiner S, Luo X, Lin HM, Sessler DI, Saager L, Sieber FE, Lee HB, Sano M; and the Dexlirium Writing Group; Jankowski C, Bergese SD, Candiotti K, Flaherty JH, Arora H, Shander A, Rock P. Intraoperative Infusion of Dexmedetomidine for Prevention of Postoperative Delirium and Cognitive Dysfunction in Elderly Patients Undergoing Major Elective Noncardiac Surgery: A Randomized Clinical Trial. JAMA Surg. 2017 Aug 16;152(8):e171505. doi: 10.1001/jamasurg.2017.1505. Epub 2017 Aug 16. |
Not provided
Not provided
Not provided
Trial was conducted at 10 sites from February 2008 to May 2014. The lead site was The Mount Sinai Hospital in New York City.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Precedex | Precedex (Dexmedetomidine) 0.5/ug/kg/hr |
| FG001 | Placebo | Placebo - normal saline 0.5/ug/kg/hr |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | 0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively. |
|
|
Number of participants with intraoperative bradycardia
| day 1 |
| Intraoperative Hypotension | Number of participants with intraoperative hypotension | day 1 |
| Intraoperative Hypertension | Number of participants with intraoperative hypertension | day 1 |
| Length of Stay | Length of Stay (LOS) in the hospital | average 4 days |
| Baltimore |
| Maryland |
| 21224 |
| United States |
| University of Maryland | College Park | Maryland | 20742 | United States |
| The Mayo Clinic | Rochester | Minnesota | 55905 | United States |
| St. Louis University | St Louis | Missouri | 63104 | United States |
| Englewood Hospital & Medical Center | Englewood | New Jersey | 07631 | United States |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | United States |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | United States |
| Cleveland Clinic | Cleveland | Ohio | 44195 | United States |
| Ohio State University | Columbus | Ohio | 43210 | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Precedex | Precedex (Dexmedetomidine) 0.5/ug/kg/hr |
| BG001 | Placebo | Placebo - normal saline 0.5/ug/kg/hr |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median | Inter-Quartile Range | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Education | Median | Inter-Quartile Range | years |
| |||||||||||||||
| Body Mass Index (BMI) | Median | Inter-Quartile Range | kg/m^2 |
| |||||||||||||||
| Anesthesia Time | Median | Inter-Quartile Range | minutes |
| |||||||||||||||
| Surgical Time | Median | Inter-Quartile Range | minutes |
| |||||||||||||||
| Mild Cognitive Impairment (MCI) | Count of Participants | Participants |
| ||||||||||||||||
| ASA Status | The American Society of Anesthesiologists (ASA) Physical Status classification:
| Count of Participants | Participants |
| |||||||||||||||
| Coronary Artery Disease (CAD) | Count of Participants | Participants |
| ||||||||||||||||
| Hypertension (HTN) | Count of Participants | Participants |
| ||||||||||||||||
| Congestive Heart Failure (CHF) | Count of Participants | Participants |
| ||||||||||||||||
| Diabetes (DM) | Count of Participants | Participants |
| ||||||||||||||||
| Cancer (CA) | Count of Participants | Participants |
| ||||||||||||||||
| Surgical Procedure | Count of Participants | Participants |
| ||||||||||||||||
| Dosage of Fentanyl used prior to this study | amount of general anesthesia given | Median | Inter-Quartile Range | µg/h |
| ||||||||||||||
| Propofol | amount of general anesthesia given | Median | Inter-Quartile Range | mg/kg |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Delirium Battery | Number of Participants with occurrence of Post-Operative Delirium in Post-Anesthesia Care Unit (PACU) | Posted | Count of Participants | Participants | Day 1 |
|
|
| |||||||||||||||||||||||||||||||||||||
| Secondary | Neuropsychological Testing | Rate of change of cognitive function - data not collected because secondary analysis which was not performed | Posted | at 3 months postoperatively |
|
| ||||||||||||||||||||||||||||||||||||||||
| Secondary | Intraoperative Bradycardia | Number of participants with intraoperative bradycardia | Posted | Count of Participants | Participants | day 1 |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Intraoperative Hypotension | Number of participants with intraoperative hypotension | Posted | Count of Participants | Participants | day 1 |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Intraoperative Hypertension | Number of participants with intraoperative hypertension | Posted | Count of Participants | Participants | day 1 |
|
| ||||||||||||||||||||||||||||||||||||||
| Secondary | Length of Stay | Length of Stay (LOS) in the hospital | Posted | Median | Inter-Quartile Range | days | average 4 days |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Precedex | Precedex (Dexmedetomidine) 0.5/ug/kg/hr | 1 | 189 | 12 | 189 | 0 | 189 |
| EG001 | Placebo | Placebo - normal saline 0.5/ug/kg/hr | 3 | 201 | 9 | 201 | 0 | 201 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Myocardial Infarction | Cardiac disorders |
| |||
| Unstable Angina | Cardiac disorders |
| |||
| New Arrhythmia | Cardiac disorders |
| |||
| Pulmonary Edema | Respiratory, thoracic and mediastinal disorders |
| |||
| Heart Failure | Cardiac disorders |
| |||
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders |
| |||
| Penumonia | Respiratory, thoracic and mediastinal disorders |
| |||
| Stroke | Vascular disorders |
| |||
| Venous Thrombosis | Vascular disorders |
| |||
| Pulmonary Embolus | Vascular disorders |
| |||
| Renal Failure | Renal and urinary disorders |
| |||
| GI Bleed | Gastrointestinal disorders |
| |||
| Other Infection | Infections and infestations |
| |||
| Death | General disorders |
|
Not provided
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Stacie Deiner | Icahn School of Medicine at Mount Sinai | 212-241-7749 | stacie.deiner@mountsinai.org |
| ID | Term |
|---|---|
| D000071257 | Emergence Delirium |
| D000079690 | Postoperative Cognitive Complications |
| ID | Term |
|---|---|
| D003693 | Delirium |
| D003221 | Confusion |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D019965 | Neurocognitive Disorders |
| D001523 | Mental Disorders |
| D060825 | Cognitive Dysfunction |
| D003072 | Cognition Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D020927 | Dexmedetomidine |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
| Male |
|
| 3 |
|
| 4 |
|
| Thoracic |
|
| Orthopedic |
|
| Urologic |
|
| General |
|
| Both |
|
| None |
|
|
|
|
|